Search Results - "ROONEY, James F"

Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study by Grant, Robert M, Prof, Anderson, Peter L, Prof, McMahan, Vanessa, BSc, Liu, Albert, MD, Amico, K Rivet, PhD, Mehrotra, Megha, MPH, Hosek, Sybil, PhD, Mosquera, Carlos, MD, Casapia, Martin, MD, Montoya, Orlando, Buchbinder, Susan, MD, Veloso, Valdilea G, MD, Mayer, Kenneth, Prof, Chariyalertsak, Suwat, Prof, Bekker, Linda-Gail, Prof, Kallas, Esper G, MD, Schechter, Mauro, Prof, Guanira, Juan, MD, Bushman, Lane, BChem, Burns, David N, MD, Rooney, James F, MD, Glidden, David V, Prof

“…Summary Background The effect of HIV pre-exposure prophylaxis (PrEP) depends on uptake, adherence, and sexual practices. We aimed to assess these factors in a…”
Get full text

Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission by Patterson, Kristine B, Prince, Heather A, Kraft, Eric, Jenkins, Amanda J, Shaheen, Nicholas J, Rooney, James F, Cohen, Myron S, Kashuba, Angela D M

“…A mainstay of strategies to prevent HIV-1 transmission is to use antiretroviral therapy (ART) for pre-exposure prophylaxis (PrEP). Critical to the design and…”
Get more information

Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis by Havlir, Diane V, Kendall, Michelle A, Ive, Prudence, Kumwenda, Johnstone, Swindells, Susan, Qasba, Sarojini S, Luetkemeyer, Anne F, Hogg, Evelyn, Rooney, James F, Wu, Xingye, Hosseinipour, Mina C, Lalloo, Umesh, Veloso, Valdilea G, Some, Fatuma F, Kumarasamy, N, Padayatchi, Nesri, Santos, Breno R, Reid, Stewart, Hakim, James, Mohapi, Lerato, Mugyenyi, Peter, Sanchez, Alejandro, Sanchez, Jorge, Lama, Javier R, Pape, Jean W, Asmelash, Aida, Moko, Evans, Sawe, Fred, Andersen, Janet, Sanne, Ian

“…In this international study involving 809 patients with HIV and TB coinfection, earlier therapy for both infections, versus waiting 8 to 12 weeks to initiate…”
Get full text

Abacavir/Lamivudine Versus Tenofovir DF/Emtricitabine as Part of Combination Regimens for Initial Treatment of HIV: Final Results by Sax, Paul E., Tierney, Camlin, Collier, Ann C., Daar, Eric S., Mollan, Katie, Budhathoki, Chakra, Godfrey, Catherine, Jahed, Nasreen C., Myers, Laurie, Katzenstein, David, Farajallah, Awny, Rooney, James F., Ha, Belinda, Woodward, William C., Feinberg, Judith, Tashima, Karen, Murphy, Robert L., Fischl, Margaret A.

“…Background. AIDS Clinical Trials Group A5202 compared blinded abacavir/lamivudine (ABC/3TC) to tenofovir DF/emtricitabine (TDF/FTC) with efavirenz (EFV) or…”
Get full text

Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers by Mutua, Gaudensia, Sanders, Eduard, Mugo, Peter, Anzala, Omu, Haberer, Jessica E, Bangsberg, David, Barin, Burc, Rooney, James F, Mark, David, Chetty, Paramesh, Fast, Patricia, Priddy, Frances H

“…Little is known about safety of and adherence to intermittent HIV PrEP regimens, which may be more feasible than daily dosing in some settings. We present…”
Get full text

In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide by Rohan, Lisa C, Moncla, Bernard J, Kunjara Na Ayudhya, Ratiya Pamela, Cost, Marilyn, Huang, Yunda, Gai, Fang, Billitto, Nicole, Lynam, J D, Pryke, Kara, Graebing, Phillip, Hopkins, Nicole, Rooney, James F, Friend, David, Dezzutti, Charlene S

“…Tenofovir gel has entered into clinical trials for use as a topical microbicide to prevent HIV-1 infection but has no published data regarding pre-clinical…”
Get full text

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment by Haubrich, Richard H, Riddler, Sharon A, DiRienzo, A Gregory, Komarow, Lauren, Powderly, William G, Klingman, Karin, Garren, Kevin W, Butcher, David L, Rooney, James F, Haas, David W, Mellors, John W, Havlir, Diane V

“…The metabolic effects of initial therapy for HIV-1 infection are important determinants of regimen selection. Open-label study in 753 subjects randomized…”
Get full text

Risk of tuberculosis after initiation of antiretroviral therapy among persons with HIV in Europe by Johansen, Isik S., Roen, Ashley, Kraef, Christian, Martín-Iguacel, Raquel, Nemeth, Johannes, Fenner, Lukas, Zangerle, Robert, Llibre, Josep M., Miller, Robert F., Suarez, Isabelle, de Wit, Stephane, Wit, Ferdinand, Mussini, Christina, Saracino, Annalisa, Canetti, Diana, Volny-Anne, Alain, Jaschinski, Nadine, Neesgaard, Bastian, Ryom, Lene, Peters, Lars, Garges, Harmony P., Rooney, James F., Podlekareva, Daria, Mocroft, Amanda, Kirk, Ole

“…•The tuberculosis (TB) risk after antiretroviral treatment (ART) initiation in Europe is studied.•TB peaked within 3 months post ART (14.41/1000 PY).•TB was…”
Get full text

The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults : the first 4 years by NELSON, Mark R, KATLAMA, Christine, CURTIS, Sue, CHEN, Shan-Shan, SMITH, Stephen, BISCHOFBERGER, Norbert, ROONEY, James F, MONTANER, Julio S, COOPER, David A, GAZZARD, Brian, CLOTET, Bonaventura, LAZZARIN, Adriano, SCHEWE, Knud, LANGE, Joep, WYATT, Christina

“…To characterize the safety profile of tenofovir disoproxil fumarate (DF) for the treatment of HIV infection in adults over the first 4 years of use. A…”
Get full text

Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial by Kibengo, Freddie M, Ruzagira, Eugene, Katende, David, Bwanika, Agnes N, Bahemuka, Ubaldo, Haberer, Jessica E, Bangsberg, David R, Barin, Burc, Rooney, James F, Mark, David, Chetty, Paramesh, Fast, Patricia, Kamali, Anatoli, Priddy, Frances H

“…Efficacy of oral pre-exposure prophylaxis (PrEP) in prevention of HIV acquisition has been evaluated using a daily regimen. However, adherence to long term…”
Get full text

A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206 by TUNGSIRIPAT, Marisa, KITCH, Douglas, GLESBUY, Marshall J, GUPTA, Samir K, MELLORS, John W, MORAN, Laura, JONES, Lynne, ALSTON-SMITH, Beverly, ROONEY, James F, ABERG, Judith A

“…Several studies have reported improvement in lipids after antiretroviral therapy switches to tenofovir disoproxil fumarate (TDF)-containing regimens. We…”
Get full text

Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial by Thurman, Andrea R., Schwartz, Jill L., Cottrell, Mackenzie L., Brache, Vivian, Chen, Beatrice A., Cochón, Leila, Ju, Susan, McGowan, Ian, Rooney, James F., McCallister, Scott, Doncel, Gustavo F.

“…Daily oral emtricitabine (FTC, F)/tenofovir disoproxil fumarate (TDF) combination is approved for HIV pre-exposure prophylaxis (PrEP) in men and women…”
Get full text

In-utero exposure to tenofovir disoproxil fumarate pre-exposure prophylaxis and growth metrics in HIV unexposed breastfed infants in South Africa: a post hoc analysis of the CAP 016 PrEP in pregnancy RCT by Naidoo, Megeshinee, Naidoo, Kimesh L, Lombard, Carl, Desmond, Alicia C, Clark, Richard, Rooney, James F, Gray, Glenda, Moodley, Dhayendre

“…We evaluated growth metrics in HIV unexposed African breastfed infants in the first 18 months of life in association with exposure to Tenofovir Diphosphate…”
Get full text

Evaluation of Xpert point-of-care assays for detection of HIV infection in persons using long-acting cabotegravir for pre-exposure prophylaxis by Fogel, Jessica M, Piwowar-Manning, Estelle, Moser, Amber, Hill, Tinia, Ahmed, Shahnaz, Cummings, Vanessa, Mostafa, Heba H, Wang, Zhe, Jennings, Andrea, Gallardo-Cartagena, Jorge A, Figueroa, María Inés, St Clair, Marty, Rinehart, Alex R, Adeyeye, Adeola, Rooney, James F, Cohen, Myron S, Grinsztejn, Beatriz, Landovitz, Raphael J, Eshleman, Susan H

“…Detection of HIV infection may be challenging in persons using long-acting cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) due to viral suppression and…”
Get full text

Natural Substrate Concentrations Can Modulate the Prophylactic Efficacy of Nucleotide HIV Reverse Transcriptase Inhibitors by GARCIA-LERMA, J. Gerardo, AUNG, Wutyi, YEN-CHIN LIN, Carol, HANSON, Debra L, KERSH, Ellen, PAU, Chou-Pong, RAY, Adrian S, ROONEY, James F, LEE, William A, HENEINE, Walid, CONG, Mian-Er, QI ZHENG, YOUNGPAIROJ, Ae S, MITCHELL, James, HOLDER, Angela, MARTIN, Amy, KUKLENYIK, Susan, WEI LUO

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Pharmacokinetics and Safety of Single-Dose Tenofovir Disoproxil Fumarate and Emtricitabine in HIV-1-Infected Pregnant Women and Their Infants by FLYNN, Patricia M, MIROCHNICK, Mark, KEARNEY, Brian, MOFENSON, Lynne M, HEATHER WATTS, D, JEAN-PHILIPPE, Patrick, HECKMAN, Barbara, THORPE, Edwin, COTTER, Amanda, PURSWANI, Murli, SHAPIRO, David E, BARDEGUEZ, Arlene, RODMAN, John, ROBBINS, Brian, HUANG, Sharon, FISCUS, Susan A, VAN ROMPAY, Koen K. A, ROONEY, James F

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic Implant by Pons-Faudoa, Fernanda P, Trani, Nicola Di, Sizovs, Antons, Shelton, Kathryn A, Momin, Zoha, Bushman, Lane R, Xu, Jiaqiong, Lewis, Dorothy E, Demaria, Sandra, Hawkins, Trevor, Rooney, James F, Marzinke, Mark A, Kimata, Jason T, Anderson, Peter L, Nehete, Pramod N, Arduino, Roberto C, Sastry, K Jagannadha, Grattoni, Alessandro

“…HIV-1 is a chronic disease managed by strictly adhering to daily antiretroviral therapy (ART). However, not all people living with HIV-1 have access to ART,…”
Get full text

An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM by Hosek, Sybil G, Rudy, Bret, Landovitz, Raphael, Kapogiannis, Bill, Siberry, George, Rutledge, Brandy, Liu, Nancy, Brothers, Jennifer, Mulligan, Kathleen, Zimet, Gregory, Lally, Michelle, Mayer, Kenneth H, Anderson, Peter, Kiser, Jennifer, Rooney, James F, Wilson, Craig M

“…BACKGROUND:Young men who have sex with men (YMSM) are a key population for implementation of preexposure prophylaxis (PrEP) interventions. This open-label…”
Get full text

On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection by Molina, Jean-Michel, Capitant, Catherine, Spire, Bruno, Pialoux, Gilles, Cotte, Laurent, Charreau, Isabelle, Tremblay, Cecile, Le Gall, Jean-Marie, Cua, Eric, Pasquet, Armelle, Raffi, François, Pintado, Claire, Chidiac, Christian, Chas, Julie, Charbonneau, Pierre, Delaugerre, Constance, Suzan-Monti, Marie, Loze, Benedicte, Fonsart, Julien, Peytavin, Gilles, Cheret, Antoine, Timsit, Julie, Girard, Gabriel, Lorente, Nicolas, Préau, Marie, Rooney, James F, Wainberg, Mark A, Thompson, David, Rozenbaum, Willy, Doré, Veronique, Marchand, Lucie, Simon, Marie-Christine, Etien, Nicolas, Aboulker, Jean-Pierre, Meyer, Laurence, Delfraissy, Jean-François

“…In this trial of preexposure prophylaxis with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) in men who have sex with men, TDF-FTC was found to be…”
Get full text

Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083 by Marzinke, Mark A, Grinsztejn, Beatriz, Fogel, Jessica M, Piwowar-Manning, Estelle, Li, Maoji, Weng, Lei, McCauley, Marybeth, Cummings, Vanessa, Ahmed, Shahnaz, Haines, Casey D, Bushman, Lane R, Petropoulos, Christos, Persaud, Deborah, Adeyeye, Adeola, Kofron, Ryan, Rinehart, Alex, St Clair, Marty, Rooney, James F, Pryluka, Daniel, Coelho, Lara, Gaur, Aditya, Middelkoop, Keren, Phanuphak, Nittaya, Cohen, Myron S, Hendrix, Craig W, Anderson, Peter, Hanscom, Brett, Donnell, Deborah, Landovitz, Raphael J, Eshleman, Susan H

“…Abstract Background The HIV Prevention Trials Network (HPTN) 083 trial demonstrated that long-acting cabotegravir (CAB-LA) was more effective than tenofovir…”
Get full text